Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice

Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group, E.G. Giannini, A. Aglitti, M. Borzio, M. Gambato, M. Guarino, M. Iavarone, Q. Lai, G.B.L. Sandri, F. Melandro, F. Morisco, F.R. Ponziani, M. Rendina, F.P. Russo, R. Sacco, M. Viganò, A. Vitale, F. Trevisani

Research output: Contribution to journalArticle

Original languageEnglish
Article number1689
JournalCancers
Volume11
Issue number11
DOIs
Publication statusPublished - 2019

Keywords

  • Check-point inhibitors
  • Immunotherapy
  • Liver disease
  • Outcome
  • atezolizumab
  • bevacizumab
  • camrelizumab
  • checkpoint kinase inhibitor
  • durvalumab
  • ipilimumab
  • lenvatinib
  • nivolumab
  • pembrolizumab
  • ticilimumab
  • tislelizumab
  • cancer adjuvant therapy
  • cancer combination chemotherapy
  • cancer immunotherapy
  • cellular, subcellular and molecular biological phenomena and functions
  • clinical practice
  • data base
  • drug efficacy
  • human
  • immune checkpoint blockade therapy
  • immunobiology
  • intestine flora
  • liver cell carcinoma
  • molecularly targeted therapy
  • monotherapy
  • nonhuman
  • patient selection
  • response evaluation criteria in solid tumors
  • Review
  • T cell exhaustion
  • treatment response

Cite this

Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group, Giannini, E. G., Aglitti, A., Borzio, M., Gambato, M., Guarino, M., ... Trevisani, F. (2019). Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers, 11(11), [1689]. https://doi.org/10.3390/cancers11111689

Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. / Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group ; Giannini, E.G.; Aglitti, A.; Borzio, M.; Gambato, M.; Guarino, M.; Iavarone, M.; Lai, Q.; Sandri, G.B.L.; Melandro, F.; Morisco, F.; Ponziani, F.R.; Rendina, M.; Russo, F.P.; Sacco, R.; Viganò, M.; Vitale, A.; Trevisani, F.

In: Cancers, Vol. 11, No. 11, 1689, 2019.

Research output: Contribution to journalArticle

Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group, Giannini, EG, Aglitti, A, Borzio, M, Gambato, M, Guarino, M, Iavarone, M, Lai, Q, Sandri, GBL, Melandro, F, Morisco, F, Ponziani, FR, Rendina, M, Russo, FP, Sacco, R, Viganò, M, Vitale, A & Trevisani, F 2019, 'Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice', Cancers, vol. 11, no. 11, 1689. https://doi.org/10.3390/cancers11111689
Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group ; Giannini, E.G. ; Aglitti, A. ; Borzio, M. ; Gambato, M. ; Guarino, M. ; Iavarone, M. ; Lai, Q. ; Sandri, G.B.L. ; Melandro, F. ; Morisco, F. ; Ponziani, F.R. ; Rendina, M. ; Russo, F.P. ; Sacco, R. ; Viganò, M. ; Vitale, A. ; Trevisani, F. / Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. In: Cancers. 2019 ; Vol. 11, No. 11.
@article{ac850088adb74de2a392f4596fdc5b57,
title = "Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice",
keywords = "Check-point inhibitors, Immunotherapy, Liver disease, Outcome, atezolizumab, bevacizumab, camrelizumab, checkpoint kinase inhibitor, durvalumab, ipilimumab, lenvatinib, nivolumab, pembrolizumab, ticilimumab, tislelizumab, cancer adjuvant therapy, cancer combination chemotherapy, cancer immunotherapy, cellular, subcellular and molecular biological phenomena and functions, clinical practice, data base, drug efficacy, human, immune checkpoint blockade therapy, immunobiology, intestine flora, liver cell carcinoma, molecularly targeted therapy, monotherapy, nonhuman, patient selection, response evaluation criteria in solid tumors, Review, T cell exhaustion, treatment response",
author = "{Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group} and E.G. Giannini and A. Aglitti and M. Borzio and M. Gambato and M. Guarino and M. Iavarone and Q. Lai and G.B.L. Sandri and F. Melandro and F. Morisco and F.R. Ponziani and M. Rendina and F.P. Russo and R. Sacco and M. Vigan{\`o} and A. Vitale and F. Trevisani",
note = "Export Date: 18 November 2019 Correspondence Address: Giannini, E.G.; Gastroenterology Unit, Department of Internal Medicine, Universit{\`a} di Genova IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico)-Ospedale Policlinico San MartinoItaly",
year = "2019",
doi = "10.3390/cancers11111689",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "11",

}

TY - JOUR

T1 - Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice

AU - Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group

AU - Giannini, E.G.

AU - Aglitti, A.

AU - Borzio, M.

AU - Gambato, M.

AU - Guarino, M.

AU - Iavarone, M.

AU - Lai, Q.

AU - Sandri, G.B.L.

AU - Melandro, F.

AU - Morisco, F.

AU - Ponziani, F.R.

AU - Rendina, M.

AU - Russo, F.P.

AU - Sacco, R.

AU - Viganò, M.

AU - Vitale, A.

AU - Trevisani, F.

N1 - Export Date: 18 November 2019 Correspondence Address: Giannini, E.G.; Gastroenterology Unit, Department of Internal Medicine, Università di Genova IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico)-Ospedale Policlinico San MartinoItaly

PY - 2019

Y1 - 2019

KW - Check-point inhibitors

KW - Immunotherapy

KW - Liver disease

KW - Outcome

KW - atezolizumab

KW - bevacizumab

KW - camrelizumab

KW - checkpoint kinase inhibitor

KW - durvalumab

KW - ipilimumab

KW - lenvatinib

KW - nivolumab

KW - pembrolizumab

KW - ticilimumab

KW - tislelizumab

KW - cancer adjuvant therapy

KW - cancer combination chemotherapy

KW - cancer immunotherapy

KW - cellular, subcellular and molecular biological phenomena and functions

KW - clinical practice

KW - data base

KW - drug efficacy

KW - human

KW - immune checkpoint blockade therapy

KW - immunobiology

KW - intestine flora

KW - liver cell carcinoma

KW - molecularly targeted therapy

KW - monotherapy

KW - nonhuman

KW - patient selection

KW - response evaluation criteria in solid tumors

KW - Review

KW - T cell exhaustion

KW - treatment response

U2 - 10.3390/cancers11111689

DO - 10.3390/cancers11111689

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 11

M1 - 1689

ER -